1. Introduction {#sec1}
===============

Liver transplantation (LT) is one of the most effective treatments for end-stage liver disease as well as for cases of acute liver failure. The shortage of donors is a major challenge in liver transplantation, bringing higher waiting-list mortality rate \[[@B1]\]. Therefore, liver transplant teams maximized their search strategies to increase the pool of available liver grafts. Donor pool broadening strategies such as the use of marginal organs, steatosis greater than 30%, donors over 60 years, grafts with a cold ischemia time\>12h, donors with hypernatremia, positive serologies for hepatitis B virus (HBV) or hepatitis C virus (HCV), cadaveric split livers, and living donors are being pursed \[[@B2]\].

Currently, the global prevalence of NAFLD is around 25% \[[@B3]\], signifying the pool of potential liver donor is now frequently populated by those with fatty liver disease. However, the use of fatty liver is still controversial. It is believed that donor liver steatosis was associated with a higher risk of primary nonfunction (PNF), early graft dysfunction (EAD), and poor graft survival rate. But, in recent years, several studies demonstrated excellent perioperative and long-term outcomes with the use of grafts with steatosis \>30% \[[@B4]--[@B8]\]. Therefore, the purpose of this meta-analysis was to analyze the impact of donor steatosis on the outcome of liver transplantation.

2. Materials and Methods {#sec2}
========================

This systematic review and meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline.

2.1. Search Strategy {#sec2.1}
--------------------

Two researchers independently performed a comprehensive search of PubMed, Embase, the Cochrane library, China National Knowledge Infrastructure, Wanfang database, Google Scholar, "<http://cn.Bing.com/academic>", "<http://xueshu.baidu.com/>", "<http://www.gycc.com/>", Scopus and ISI/web of knowledge database, using the method of free words and subjects. Meanwhile, two researchers independently performed systematic searches in SIGLE, Open Grey, NTlS, and Grey Net International for gray literature to obtain more comprehensive, accurate, and objective research conclusions. Key search terms were "fatty liver", "steatosis", "nonalcoholic fatty liver disease donor", and "liver transplantation". Databases were searched from the earliest data to 31 May 2018.

2.2. Study Selection {#sec2.2}
--------------------

We included all liver transplant patients with fatty liver as donor for research. We excluded researches that could not extract valid data, studies where the degree of steatosis was not clear, review articles, case reports, letters, editorials, cohorts with fewer than 5 patients, studies published only as abstracts, nonhuman studies, and non-English language studies. The two researchers searched the literature individually and any disputes were discussed or agreed by the third senior author until the opinions were agreed.

2.3. Data Extraction {#sec2.3}
--------------------

The two researchers separately extracted literature-related data: (1) the name of the first author, (2) publication year, (3) country, (4) number of patients, (5) study design, (6) the enrolment period, (7) follow-up period, and (8) outcomes.

The outcomes of interest we concerned were as follows: primary nonfunction (PNF) rate, early graft dysfunction (EAD) rate, graft survival rate, patient survival rate. PNF was defined as the need for urgent retransplantation when a graft never demonstrated any evidence of initial function following transplantation in the absence of any vascular complication \[[@B9]\]. EAD was defined as follows: (1) bilirubin 170 mmol/L on postoperative day (POD) 7; (2) international normalized ratio (INR) 1.6 on POD 7; (3) aminotransferase level (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) \>2000 IU/ml from day 1 to day 7 after LT \[[@B10]\].

2.4. Quality and Risk of Bias Assessment {#sec2.4}
----------------------------------------

The quality of the studies was assessed using a modified Newcastle-Ottawa scale \[[@B11]\]. The Newcastle-Ottawa Quality Assessment Form was used to evaluate the study quality for case-control studies and cohort studies. There are three parts in this assessment form, including selection, comparability, and outcome. Selection, comparability, and outcome domain can be given a maximum of 4, 2, 3 points, respectively. A study scoring a total of 8 or 9 points can be regarded as a high-quality study. A study scoring fewer than 6 points can be regarded as a low-quality study. Other studies can be regarded as moderate-quality studies. We used a fixed-effects model to obtain a summary estimate of outcomes of interest when there is no significant evidence of statistical heterogeneity among the studies. Differences between groups are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). A two-sided P value of \<0.05 was considered as statistically significant. Heterogeneity derived from included studies was evaluated using a Chi-squared based I^2^ statistic. The following cut-offs were used to quantify heterogeneity with the I^2^ statistic: 0±25%, low; 25±50%, moderate; and \>50%, high heterogeneity \[[@B12]\]. Statistical analysis was performed using STATA 12 statistical software (STATA Corp, College Station, Texas, USA).

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

Our initial search identified 2860 references according to the agreement for study selection, no studies gained from Chinese database according to the agreement for study selection, of which 38 full-text articles were reviewed. We excluded 19 studies including different methods of grouping (11 studies), no valid data to extract (6 studies), and unclear definition of outcome indicators (2 studies). Finally, the remaining 19 \[[@B4]--[@B8], [@B13]--[@B26]\] references were considered for inclusion. The flow chart of the selection of studies for inclusion in the meta-analysis was shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Study Characteristics {#sec3.2}
--------------------------

We included 19 studies in the present meta-analysis according to the inclusion and exclusion criteria, including 3 case-control studies and 16 cohort studies. A total of 4002 patients enrolled. The main characteristics of the studies were shown in [Table 1](#tab1){ref-type="table"}.

3.3. Quality Assessment and Risk of Bias {#sec3.3}
----------------------------------------

The quality of the studies was shown in Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"} in details. 6 studies scoring 8 or 9 are considered high quality. Among these, 3 case-control studies were all regarded as high quality. 4 studies scoring fewer than 6 are considered low quality. Other studies were regarded as moderate-quality studies.

3.4. Outcomes Analyses {#sec3.4}
----------------------

The experiments were grouped according to the degree of steatosis, including no steatosis, mild (\<30%) steatosis, moderate (30-60%) steatosis, and severe (\>60%) steatosis \[[@B26]\]. For the convenience of expression, we defined the group of no steatosis as control group. At the same time, we defined the group of mild steatosis, the group of moderate steatosis, and the group of severe steatosis as mild group, moderate group, and severe group. The outcomes of liver transplantation were evaluated by the following parameters: PNF rate, EAD rate, graft survival rate, and patient survival rate. We determined the impact of steatosis on posttransplant outcomes by comparing differences in outcomes between groups.

### 3.4.1. Primary Nonfunction Rate {#sec3.4.1}

10 studies reported PNF rate. PNF rate was found to be comparable between the group of no steatosis (control group) and the group of mild steatosis (mild group) (OR=0.52; 95% CI, 0.429 to 1.639; P=0.605; [Figure 2(a)](#fig2){ref-type="fig"}). No significant risk of publication bias was found as shown in Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}. However, significant differences were seen between the group of no steatosis (control group) and the group of moderate steatosis (moderate group) (OR=2.99; 95% CI, 0.128 to 0.652; P=0.003; [Figure 2(b)](#fig2){ref-type="fig"}). Similar result was also found between control group and the group of severe steatosis (severe group) (OR=6.03; 95% CI, 0.026 to 0.156; P\<0.001; [Figure 2(c)](#fig2){ref-type="fig"}). No significant heterogeneity among the studies was found and the fixed-effects model was performed shown in [Figure 2](#fig2){ref-type="fig"}.

### 3.4.2. Early Graft Dysfunction Rate {#sec3.4.2}

The meta-analysis including 8 studies showed no significance in EAD rate between control group and mild group (OR=0.77; 95% CI, 0.583 to 1.265; P=0.44; [Figure 3(a)](#fig3){ref-type="fig"}). Without significant evidence of statistical heterogeneity among the studies, the fixed-effects model was applied (I^2^=0.0%; P=0.707; [Figure 3(a)](#fig3){ref-type="fig"}). No significant risk of publication bias was found and details were shown in Supplementary [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}. Similar to the outcome of PNF rate, the EAD rate was significantly higher in moderate group compared with control group (OR=4.07; 95% CI, 0.215 to 0.584; P\<0.001; [Figure 3(b)](#fig3){ref-type="fig"}). The I^2^ statistic (I^2^=0.0%; P=0.636; [Figure 3(b)](#fig3){ref-type="fig"}) showed no significant heterogeneity among the studies and the fixed-effects model was applied. Meanwhile, significant differences were seen between control group and severe group (OR=4.84; 95% CI, 0.13 to 0.422; P\<0.001; [Figure 3(c)](#fig3){ref-type="fig"}). The importance of heterogeneity was minimal (I^2^=0.0%; P=0.665). Thus, fixed-effects model was applied ([Figure 3(c)](#fig3){ref-type="fig"}).

### 3.4.3. Graft Survival Rate {#sec3.4.3}

We also conducted an analysis for 1-year graft survival rate between groups. Surprisingly, no significantly differences were seen among groups (control group and mild group, OR=1.61; 95% CI, 0.936 to 1.978; P=0.107; [Figure 4(a)](#fig4){ref-type="fig"}) (control group and moderate group, OR=0.33; 95% CI, 0.418 to 3.393; P=0.744; [Figure 4(b)](#fig4){ref-type="fig"}) (control group and severe group, OR=0.29; 95% CI, 0.298 to 2.454; P=0.771; [Figure 4(c)](#fig4){ref-type="fig"}). No significant evidence of statistical heterogeneity was found between control group and mild group (I^2^=0.0%; P=0.503; [Figure 4(a)](#fig4){ref-type="fig"}). The same as the heterogeneity between control group and moderate group (I^2^=0.0%; P=0.588; [Figure 4(b)](#fig4){ref-type="fig"}). The fixed-effects model was applied. No significant heterogeneity was found among the studies and fixed-effects model was used (I^2^=32.4%; P=0.224; [Figure 4(c)](#fig4){ref-type="fig"}). Further meta-analysis was limited by small sample size, although we extracted the graft survival rate of one month, three months, six months, and 1 year.

### 3.4.4. Patient Survival Rate {#sec3.4.4}

We extracted data of 1-year patient survival rate, 3-year patient survival rate, 5-year patient survival rate, and 10-year patient survival rate. Ultimately, 1-year and 3-year patient survival rates were analyzed in the present meta-analysis. No significant difference was found among groups in 1-year survival rate (control group and mild group, OR=1.94; 95% CI, 0.996 to 1.992; P=0.053; [Figure 5(a)](#fig5){ref-type="fig"}) (control group and moderate group, OR=0.46; 95% CI, 0.572 to 2.465; P=0.644; [Figure 5(b)](#fig5){ref-type="fig"}) (control group and severe group, OR=0.25; 95% CI, 0.275 to 2.721; P=0.805; [Figure 5(c)](#fig5){ref-type="fig"}). There was a low statistical heterogeneity among the studies and fixed-effects model was applied. For 3-year patient survival, the outcome was analyzed in four studies with a low heterogeneity between control group and mild group (I^2^=0.0%, P=0.924, [Figure 6(a)](#fig6){ref-type="fig"}), which did not differ significantly between them (OR=0.89; 95% CI, 0.789 to 1.873; P=0.376; [Figure 6(a)](#fig6){ref-type="fig"}). Also, there was no significant differences between control group and severe group (OR=0.71; 95% CI, 0.554 to 3.545; P=0.476; [Figure 6(b)](#fig6){ref-type="fig"}) with a minimal heterogeneity (I^2^=0.0%; P=0.526; [Figure 6(b)](#fig6){ref-type="fig"}). However, further analysis between control group and moderate group was unable to be analyzed because of insufficient size of studies.

4. Discussion {#sec4}
=============

Liver transplantation (LT) is an established life-saving operation for patients with end-stage liver disease and acute liver failure. Imbalance between organ shortage and higher waiting-list mortality rate persuaded liver transplant team to use marginal donor liver to expand the donor pool. The aim of this meta-analysis was to examine the impact of steatosis on the outcome of liver transplantation.

As we know, there are two patterns of hepatic steatosis, microvascular and macrovesicular. Microvascular steatosis refers to the accumulation of tiny lipid droplets measuring \<1 mm giving a foamy appearance of the cytoplasm. It is commonly considered that microsteatosis is not relevant when selecting liver grafts for LT. Macrovesicular steatosis is defined by the presence of small to large droplets that may end up occupying the whole cytoplasm. The volume of large droplet macrosteatosis in the liver graft is closely linked to its suitability for transplantation. There were a large number of studies about macrovesicular steatosis, accounting for a large proportion of our research. We included an article about microvascular in the analysis. Since no unacceptable heterogeneity was observed and there was no significant difference for the results after removing the article, we reserved it.

EASL Clinical Practice Guidelines \[[@B27]\] proposed that mild macrosteatosis (\<30% volume) was considered suitable for transplantation. This statement was consistent with the results of our analysis. We did not observe higher primary nonfunction rates and early graft dysfunction rates in mild group compared with control group. Simultaneously, liver with mild steatosis did not increase patient survival rates and grafts survival rates. These findings supported that liver with mild steatosis can be used as a safe donor for liver transplantation.

For liver with moderate steatosis, large registry studies revealed that moderate steatosis was an independent prognostic factor for poor postoperative outcomes \[[@B13], [@B14]\] whereas other authors still suggested that the use of livers with moderate steatosis in well-controlled cases can be successful \[[@B5], [@B17]\]. Our analysis showed that moderate steatosis had no significant effect on survival rates compared with control group in spite of poor graft function. Our results provided a proof that livers with moderate steatosis can also be suitable liver grafts.

Severely steatotic liver grafts were all discarded in 1990s. Spitzer et al. \[[@B28]\] suggested that macrovesicular steatosis \>30% was an independent risk factor in the Donor Risk Index (DRI) lists. In recent years, several studies demonstrated that livers with \>60% macrovesicular steatosis were still acceptable for LT \[[@B8], [@B29]\]. Wong et al. \[[@B29]\] had observed excellent outcomes of using grafts with macrovesicular steatosis \>60% from brain-dead donors. The early postoperative outcomes of using severely steatotic liver grafts were impeccable with no hospital mortality, no PNF, and no EAD. Chavin et al. \[[@B8]\] carried out a research about long-term outcomes affected by the degree of donor steatosis. The overall patient survival rates and graft survival rates were similar among groups across all time points including 30-day, 1-yr, 3-yr, 5-yr, and 10-yr survival. In our study, similar to the posttransplantation outcome of moderate group, we found a significantly higher PNF rate and EAD rate in severe group while no significant difference was seen in survival rates between severe group and control group. Thus, liver with severe steatosis could also be considered as liver grafts.

A possible explanation for the different outcomes could be advanced donor age, graft donation after cardiac death, prolonged donor warm ischaemia time (DWIT), and prolonged cold ischemia time (CIT). And CIT was considered as a key factor among them. It is well known that hepatic steatosis is defined as the accumulation of droplets of fat in the hepatocytes. The narrowed sinusoidal lumens caused by swollen fatty hepatocytes increase intrahepatic vascular resistance and, thus, decrease the sinusoidal flow which contributes to the persistent state of chronic cellular hypoxia predisposing the steatotic liver to ischemia/reperfusion injury (I/R injury). This ischemia/reperfusion injury initiates a sequence of events leading to cellular damage with early graft dysfunction. However, Westerkamp et al. \[[@B5]\] observed favorable postoperative outcomes of moderate steatotic livers by minimizing the effects of I/R injury using a strict policy to keep the CIT as short as possible. Similarly, Wong et al. \[[@B29]\] found that with a CIT\>7 hours, the peak AST in severely steatotic grafts was much higher than that in the controls and that in severely steatotic livers with a CIT\<7 hours. In addition, Tekin et al. \[[@B30]\] considered that marginal livers should be transplanted within 12 hours attributable to increased CIT, leading high risk of developing early graft dysfunction. These findings suggested that the use of steatotic livers even with moderate and severe steatosis following a strict protocol to keep the CIT as short as possible may expand the donor pool.

Apart from the preservation methods used to protect the organ from IR injury, the final posttransplantation outcome could also be linked to the changes of hepatocyte. Interestingly, several studies reported reversal or disappear of steatosis. Westerkamp et al. \[[@B5]\] found the reversal of steatosis in 82% of the donor livers with a follow-up biopsy. The degree of fatty infiltration decreased from 60-30% to 10% or less. Another study \[[@B23]\] demonstrated complete dissipation of steatosis in the steatosis\>35% group and 85% of the moderately steatotic grafts when biopsies were performed more than 10 days after liver transplantation. Similar results were also observed in animal experiments although the mechanism has not yet to be fully elucidated. These findings revealed that steatosis was not a permanent injury to the liver parenchyma. Patients can achieve good survival rates after recovering from the acute insult. Hence, moderate-to-severe steatotic livers still have the potential to be safely utilized instead of being discarded.

Our meta-analysis must be considered in light of several important limitations. Firstly, a degree of selection bias has been generated as we excluded studies published in other languages or databases. Despite this, with only a small number of studies focusing on the posttransplant outcomes of moderate-to-severe steatosis, a thoroughly meta-analysis evaluating the long-term survival rates affected by the degree of donor steatosis was unable to be performed. Thus, further high-quality studies will still be needed to confirm these results.

In conclusion, livers with mild steatosis were safe liver grafts. Moderately and severely steatotic livers could also produce favorable postoperative outcomes with a strict protocol to keep the CIT as short as possible without decreasing graft survival rate and patient survival rate. Our meta-analysis to some degree expanded the use of livers with steatosis in liver transplantation. This may further provide a potential solution for the shortage of liver donor in the future.
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###### 

The main characteristics of the included studies.

  Author                          Year   Country of origin   Number of transplants   Type of study†   Enrolment period   follow-up period
  ------------------------------- ------ ------------------- ----------------------- ---------------- ------------------ -----------------------------------------
  Andert et al \[[@B4]\]          2017   Germany             94                      Co, P            2010-2016          August 2016
                                                                                                                         
  Westerkamp et al \[[@B5]\]      2015   The Netherlands     126                     Co, P            2000-2012          July 2013
                                                                                                                         
  Yu et al \[[@B6]\]              2017   China               563                     Co, P            2010-2014          August 2010
                                                                                                                         
  Deroose et al \[[@B7]\]         2011   Netherlands         185                     Co, P            2000-2004          September 2015
                                                                                                                         
  Chavin et al \[[@B8]\]          2013   USA                 116                     Co, P            1999-2001          at least 10-year or graft loss or death
                                                                                                                         
  Teng et al \[[@B13]\]           2012   China               131                     Co, Re           2007-2008          February 2011
                                                                                                                         
  Graaf et al \[[@B14]\]          2012   Australia           255                     Co, Re           2001-2007          ns
                                                                                                                         
  Doyle et al \[[@B15]\]          2010   USA                 310                     Co, P            2002-2008          5 years
                                                                                                                         
  Noujaim et al \[[@B16]\]        2009   Brazil              118                     Co, P            2002-2008          21±19.5 months
                                                                                                                         
  Gao et al \[[@B17]\]            2009   China               48                      CaCo, Re         2003-2005          1 year
                                                                                                                         
  Frongillo et al \[[@B18]\]      2009   Italy               24                      Co, Re           2000-?             patient death or re-transplantation
                                                                                                                         
  Burra et al \[[@B19]\]          2009   Italy               116                     Co, P            1999-2001          3 years
                                                                                                                         
  Nikeghbalian et al \[[@B20]\]   2007   Iran                174                     Co, Re           1993-2006          1 year
                                                                                                                         
  McCormack et al \[[@B21]\]      2007   Switzerland         60                      CaCo, Re         2002-2006          3 years
                                                                                                                         
  Perez-Daga et al \[[@B22]\]     2006   Spain               300                     Co, Re           1997-2004          20000+days
                                                                                                                         
  Briceno et al \[[@B23]\]        2005   Spain               500                     Co, Re           ns‡                90 days
                                                                                                                         
  Verran et al \[[@B24]\]         2003   Australia           443                     Co, Re           1986-2000          14 months
                                                                                                                         
  Marsman et al \[[@B25]\]        1996   USA                 116                     CaCo, Re         1990-1994          1167 days
                                                                                                                         
  Ploeg et al \[[@B26]\]          1993   USA                 323                     Co, Re           1984-1991          ns

Type of study† (Co: cohort study, CaCo: case-control study, CaR: case report, P: prospective, Re: retrospective)

ns‡: not stat
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